Table 2 Migraine-Specific Questionnaire (MSQ) and Medical Outcome Study Short Form 36 (SF-36) baseline scores for the pooled intent-to-treat population
Baseline Scores (Mean ± SD) | |||
|---|---|---|---|
MSQ Domains | Placebo (n = 372) | Topiramate 100 mg/d (n = 384) | p value* |
Role Restriction | 51.6 ± 16.2 | 48.1 ± 17.2 | 0.008 |
Role Prevention | 68.6 ± 18.9 | 67.0 ± 19.4 | 0.285 |
Emotional Function | 57.1 ± 22.7 | 53.7 ± 24.2 | 0.087 |
SF-36 Domains | Baseline Scores (Mean ± SD) | ||
Placebo (n = 372) | Topiramate 100 mg/d (n = 384) | p-value | |
Physical Functioning | 82.0 ± 20.1 | 82.1 ± 19.4 | 0.920 |
Bodily Pain | 51.3 ± 22.9 | 51.5 ± 22.4 | 0.969 |
Vitality | 51.3 ± 19.4 | 50.8 ± 20.8 | 0.891 |
General Health | 68.0 ± 19.5 | 68.8 ± 20.2 | 0.593 |
Role-Emotional | 69.0 ± 39.3 | 70.9 ± 37.7 | 0.486 |
Role-Physical | 44.5 ± 39.9 | 44.2 ± 40.8 | 0.959 |
Mental Health | 70.7 ± 17.7 | 71.4 ± 16.7 | 0.483 |
Social Functioning | 68.5 ± 22.3 | 70.0 ± 23.5 | 0.331 |
Physical Component Summary | 43.1 ± 8.6 | 42.9 ± 9.1 | 0.767 |
Mental Component Summary | 46.9 ± 10.6 | 47.5 ± 10.2 | 0.396 |